SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS entered a multi-year global collaboration with AstraZeneca to develop and deploy two companion diagnostics for precision oncology therapies. The agreement covers the development of a Solid Tumor application into a decentralized companion diagnostic and the validation of a Hematological Oncology application for blood cancers.
Key figures
- Programs count
- 2
- Countries reach
- > 75
- Connected institutions
- > 1,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.